News | April 07, 2022
Indian pharma growth likely to moderate in FY23: ICRA
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
Colorectal Cancer Screening is now translated into multiple languages to help people worldwide understand why, when and how to screen for colorectal cancer
The accelerated use of technology in clinical trials and the shift towards virtual trials is here to stay
According to statistics, the global inhalation drug market reached US $ 25 billion in 2020
Company expects strong organic growth in sales, EBITDA in 2022
The products are based on a combination of mushrooms and cannabinoids that have achieved a strong therapeutic effect using low concentrations of THC. The treatment is expected to be launched in Israel, US and UK in H2 2022
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
According to Fortune Business Insights, the launch of new PCR-based detection techniques will lead to a surge in demand for PCR instruments in the coming years
Subscribe To Our Newsletter & Stay Updated
